Receipt of "Helsinki Committee" (IRB) Approval for the Performance of a Clinical Trial in Cocaine Addicts at the NIH

23 April, 2009

Brainsway Announces Receipt of "Helsinki Committee" (IRB) Approval for the Performance of a Clinical Trial in Cocaine Addicts at the National Institute on Drug Abuse

Brainsway Ltd. (the "Company") announces that on April 22nd, 2009, the Company received the approval of the ethics committee of the National Institute on Drug Abuse (a division of the American National Institute of Health) to perform a clinical trial to evaluate the efficacy of the Company's Deep TMS device in the treatment of cocaine addiction.

The principal investigator conducting the clinical trial will be Dr. David Gorelik.

30 subjects are expected to participate in the trial.

The trial will be funded by the National Institute on Drug Abuse, and is expected to begin in the coming weeks.

The said trial is part of the Company's strategy to perform clinical trials in human subjects to explore the efficacy of the Company's device in treating various disorders besides depression, including Alzheimer's disease, cannabis addiction, Parkinson's disease, and others disorders, as reported by the Company.